Skip to main content
Elsevier

Books in Pharmaceutical sciences

Elsevier's Pharmaceutical Sciences collection helps pharmaceutical scientists striving to optimize drug design and improve healthcare outcomes by offering comprehensive coverage of every aspect of drug development, integrating disciplines like organic chemistry, biology, and biotechnology. Focused on safety, efficacy, and formulation design, it includes specialized fields such as Clinical Pharmacology and Translational Research, providing valuable insights into the latest advancements in drug discovery.

  • Side Effects of Drugs Annual

    A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions
    • 1st Edition
    • Volume 30
    • Jeffrey K. Aronson
    • English
    The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the informative, by critically interpreting it, and by pointing to whatever is misleading.

  • Medicinal Chemistry of Anticancer Drugs

    • 1st Edition
    • Carmen Avendaño + 1 more
    • English
    Antitumor chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. The focus of Medicinal Chemistry of Anticancer Drugs is on the mechanism of action of antitumor drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents, aiming at the rationalization of the action of this type of drug, which would allow the design of new active structures.

  • Advances in Antiviral Drug Design

    • 1st Edition
    • Volume 5
    • E. De Clercq
    • English
    Regularly reviewing the "state-of-the-art" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.

  • Side Effects of Drugs Annual

    A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions
    • 1st Edition
    • Volume 29
    • Jeffrey K. Aronson
    • English
    The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the Annuals by selecting critically from each year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is misleading.

  • Elsevier's Dictionary of Vitamins and Pharmacochemistry

    • 1st Edition
    • Henry Philippsborn
    • English
    The dictionary will contain terms covering the following fields and subfields: Vitamin Technology: Vitamin biochemistry / Physiology; Origin of vitamins: natural, synthetic; Fat-soluble vitamins; Water-soluble vitamins; Vitamins as antioxidants; Vitamin deficiencies / Hypervitaminosis - Enzymes/Proteins: Biotechnology as applied biological science aimed at industrial exploitation - Hormones: Biochemistry; Physiology - Pharmaceutical Chemistry / Pharmaceutical Technology / Pharmaceutical Processes: Conception of the active principles; Structural analysis; Antibiotics and their way of action; Biochemistry; The Drug / The Medicament: Definition, origin, way of action; Biochemistry - Medical Aspects in the languages English, German, French and Portuguese.

  • Pharmacy Law and Practice

    • 4th Edition
    • Jon Merrills + 1 more
    • English
    Suitable for both students and practicing pharmacists, the latest edition of this classic textbook provides comprehensive coverage of an essential component of the U.K. pharmacy curriculum: pharmacy law and ethics. Completely rewritten since the last edition to reflect the rapid pace at which this field moves, it offers a clear, readable and non-technical guide on balancing the needs of patients with the letter of the law. It explains what happens and why in a reader-friendly format, taking a problem solving approach, and even provides an introduction to pharmacy issues for solicitors and legal personnel. Any pharmacist, student, or regulatory authority will find it appropriate for either a serious study or for answering questions which occur in practice.

  • Synthesis of Essential Drugs

    • 1st Edition
    • Ruben Vardanyan + 1 more
    • English
    Synthesis of Essential Drugs describes methods of synthesis, activity and implementation of diversity of all drug types and classes. With over 2300 references, mainly patent, for the methods of synthesis for over 700 drugs, along with the most widespread synonyms for these drugs, this book fills the gap that exists in the literature of drug synthesis. It provides the kind of information that will be of interest to those who work, or plan to begin work, in the areas of biologically active compounds and the synthesis of medicinal drugs. This book presents the synthesis of various groups of drugs in an order similar to that traditionally presented in a pharmacology curriculum. This was done with a very specific goal in mind – to harmonize the chemical aspects with the pharmacology curriculum in a manner useful to chemists. Practically every chapter begins with an accepted brief definition and description of a particular group of drugs, proposes their classification, and briefly explains the present model of their action. This is followed by a detailed discussion of methods for their synthesis. Of the thousands of drugs existing on the pharmaceutical market, the book mainly covers generic drugs that are included in the WHO’s Essential List of Drugs. For practically all of the 700+ drugs described in the book, references (around 2350) to the methods of their synthesis are given along with the most widespread synonyms. Synthesis of Essential Drugs is an excellent handbook for chemists, biochemists, medicinal chemists, pharmacists, pharmacologists, scientists, professionals, students, university libraries, researchers, medical doctors and students, and professionals working in medicinal chemistry.

  • Drug Discovery

    From Bedside to Wall Street
    • 1st Edition
    • Tamas Bartfai + 1 more
    • English
    Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

  • Amylin

    Physiology and Pharmacology
    • 1st Edition
    • Volume 52
    • Andrew Young
    • English
    Amylin deciphers amylin's physiology and reveals previously unrecognized mechanisms fundamental to control body weight and fuel homeostasis. This book also discusses therapeutic utility of amylin as the first new medicine to treat diabetes since insulin.

  • The Law and Ethics of the Pharmaceutical Industry

    • 1st Edition
    • M.N.G. Dukes
    • English
    As one of the most massive and successful business sectors, the pharmaceutical industry is a potent force for good in the community, yet its behaviour is frequently questioned: could it serve society at large better than it has done in the recent past? Its own internal ethics, both in business and science, may need a careful reappraisal, as may the extent to which the law - administrative, civil and criminal - succeeds in guiding (and where neccessary contraining) it. The rules of behavior that may be considered to apply to today's pharmaceutical industry have emerged over a very long period and the process goes on. Even the immensely detailed standards for quality, safety and efficacy laid down in drug law and regulation during the second half of the twentieth century have their limitations as tools for ensuring that the public interest is well served. In particular, national and regional regulatory agencies are heavily dependent on industrial data for their decision-making, their standards and competence vary, and even the existing network of agencies does not cover the entire world. What is more there are many areas of law and regulation affecting the industry, concerning for example the pricing of medicines, the conduct of clinical studies, the health protection of workers and concern for the environment. In some fields it is indeed hardly possible to maintain standards through regulation.Professor N.M. Graham Dukes, a physician and lawyer with long term experience in industrial research management, academic study and international drug policy, provides here a powerfully documented analysis into the way this industry thinks, acts, and is viewed, and examines the current trends pointing to change.

  • Progress in Medicinal Chemistry

    • 1st Edition
    • Volume 43
    • English
    The Progress in Medicinal Chemistry series spans a wide range of topics of interest to the drug discovery community. This particular volume touches upon the following:* The Herg ion channel * Fluorescence-based high throughput assay * Aprepitant and neurokinin receptors * Muscarinic receptor targets * Gene activation pathways * Malaria and antimalarial drugs * HIV virus mutation and new therapeuticsProgress in Medicinal Chemistry is available online on ScienceDirect — full-text online of volumes 41 onwards. Elsevier book series on ScienceDirect gives multiple users throughout an institution simultaneous online access to an important compliment to primary research. Digital delivery ensures users reliable, 24-hour access to the latest peer-reviewed content. The Elsevier book series are compiled and written by the most highly regarded authors in their fields and are selected from across the globe using Elsevier’s extensive researcher network. For more information about the Elsevier Book Series on ScienceDirect Program, please visit:http://www.inf...

  • Handbook of Pharmaceutical Analysis by HPLC

    • 1st Edition
    • Volume 6
    • Satinder Ahuja + 1 more
    • English
    High pressure liquid chromatography–frequ... called high performance liquid chromatography (HPLC or, LC) is the premier analytical technique in pharmaceutical analysis and is predominantly used in the pharmaceutical industry. Written by selected experts in their respective fields, the Handbook of Pharmaceutical Analysis by HPLC Volume 6, provides a complete yet concise reference guide for utilizing the versatility of HPLC in drug development and quality control. Highlighting novel approaches in HPLC and the latest developments in hyphenated techniques, the book captures the essence of major pharmaceutical applications (assays, stability testing, impurity testing, dissolution testing, cleaning validation, high-throughput screening).

  • Treatment of Leukemia and Lymphoma

    • 1st Edition
    • Volume 51
    • David A. Scheinberg + 1 more
    • English
    New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals... inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.

  • Profiles of Drug Substances, Excipients and Related Methodology

    • 1st Edition
    • Volume 30
    • English
    Whilst following in the footsteps of previous volumes by presenting comprehensive reviews of drug substances and additional materials, this title also heralds a significant expansion of the scope of the series. Traditional contributions will now also be augmented by publication of critical review chapters that summarize information related to the characterization of drug substances and excipients. This change is required to better meet the needs of the pharmaceutical communtiy and to allow the development of a timely vehicle for publishing review materials on this topic.The scope of the Profiles series will encompass review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodologoy related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.

  • Advances in Antiviral Drug Design

    • 1st Edition
    • Volume 4
    • E. De Clercq
    • English
    The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

  • Handbook of Isolation and Characterization of Impurities in Pharmaceuticals

    • 1st Edition
    • Volume 5
    • Satinder Ahuja + 1 more
    • English
    The United States Food and Drug Administration (FDA) and other regulatory bodies around the world require that impurities in drug substance and drug product levels recommended by the International Conference on Harmonisation (ICH) be isolated and characterized. Identifying process-related impurities and degradation products also helps us to understand the production of impurities and assists in defining degradation mechanisms. When this process is performed at an early stage, there is ample time to address various aspects of drug development to prevent or control the production of impurities and degradation products well before the regulatory filing and thus assure production of a high-quality drug product.This book, therefore, has been designed to meet the need for a reference text on the complex process of isolation and characterization of process-related (synthesis and formulation) impurities and degradation products to meet critical requlatory requirements.It's objective is to provide guidance on isolating and characterizing impurities of pharmaceuticals such as drug candidates, drug substances, and drug products. The book outlines impurity identification processes and will be a key resource document for impurity analysis, isolation/synthesis, and characterization.

  • Ethnomedicine and Drug Discovery

    • 1st Edition
    • Volume 1
    • M.M. Iwu + 1 more
    • English
    The emergence of new infectious, chronic and drug resistant diseases have prompted scientists to look towards medicinal plants as agents for treatment and prevention. This book provides an interphase between ethnomedical and ethnobotanical approaches to new drug discovery and advances in biotechnology and molecular science that has made it increasingly feasible to transform traditional medicines into modern drugs. These novel approaches also raise new issues and the volume explores economic, ethical and policy considerations of drug development based on indigenous knowledge or traditional medicine.This work also features standardization and development of phytomedicines for major therapeutic indications, including emerging infectious diseases affecting developing and developed countries.The publication provides state-of-the-art information on the most innovative science, the research, the industry, the market, and the future of ethnomedicine and drug discovery.

  • Analytical Profiles of Drug Substances and Excipients

    • 1st Edition
    • Volume 28
    • English
    Although the official compendia define a drug substance by its identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories.Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together in one source. The scope of the series has recently been expanded to include profiles of excipient materials.

  • Handbook of Modern Pharmaceutical Analysis

    • 1st Edition
    • Volume 3
    • Satinder Ahuja + 1 more
    • English
    This book describes the role modern pharmaceutical analysis plays in the development of new drugs. Detailed information is provided as to how the quality of drug products is assured from the point of discovery until the patient uses the drug. Coverage includes state-of-the-art topics such as analytics for combinatorial chemistry and high-throughput screening, formulation development, stability studies, international regulatory aspects and documentation, and future technologies that are likely to impact the field. Emphasis is placed on current, easy-to-follow methods that readers can apply in their laboratories.No book has effectively replaced the very popular text, Pharmaceutical Analysis, that was edited in the 1960s by Tak Higuchi. This book will fill that gap with an up-to-date treatment that is both handy and authoritative.

  • Analytical Profiles of Drug Substances and Excipients

    • 1st Edition
    • Volume 27
    • English
    Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories.Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together in one source. The scope of the series has recently been expanded to include profiles of excipient materials.

  • Controlled Release Veterinary Drug Delivery

    Biological and Pharmaceutical Considerations
    • 1st Edition
    • Michael J. Rathbone + 1 more
    • English
    Many controlled release veterinary drug delivery systems (CRVDDS) are presently in use, and recently there has been a host of new CRVDDS within veterinary medicine. The challenges of this area of drug delivery arise from the unique anatomy and physiology of the target animal, the cost constraints associated with the value of the animal being treated and the extended periods of time that delivery must be sustained for (often measured in months).The purpose of this book is to introduce the reader to the unique opportunities and challenges of the field of CRVDDS and to explain and discuss the basic controlled release principles underlying the development of CRVDDS. Its aim is to provide an overview of many of the areas where CRVVDS have application, and to highlight the opportunities and prospects for controlled release technology in the veterinary field.Controlled Release Veterinary Drug Delivery comprises chapters that provide workers in the field (and those interested in this area) with information on the design, development and assessment of a variety of CRVDDS. The book contains chapters that describe the relevant animal physiological and anatomical considerations alongside descriptions of current and emerging controlled release delivery systems for a variety of routes for drug delivery, and present overviews on the physical and chemical assessment of veterinary controlled release delivery systems.The veterinary area is abound with opportunities for the development of controlled release drug delivery technologies. It is an area of medicine that is open to the acceptance of novel drug delivery devices, and which readily encompasses the use of novel routes of administration. It is an area of many unmet needs, most of which offer opportunities and unique challenges for the innovative formulation scientist to provide solutions. This book will provide an insight into the biological, clinical and pharmaceutical challenges that face the formulation scientist in this interesting and diverse area of research.

  • Receptor Chemistry Towards the Third Millennium

    • 1st Edition
    • Volume 31
    • M. Gianella + 3 more
    • English
    Receptor Chemistry Towards the Third Millennium is the result of papers presented at the 12th Camerino-Noordwijker... Symposium, held in Camerino, Italy in September 1999. Although much is known about the way ligands interact with receptors, which have now been isolated, characterized and cloned, many aspects still remain to be explored. In particular, differentiation into distinct subpopulations and the multiplicity of transduction processes offer more specific targets in the search for new drugs.This book will be of interest to medicinal chemists, pharmacologists, biochemists and neurologists and will also be a valuable source of reference for medical students and postgraduate students in related fields.

  • Handbook of Non-Invasive Drug Delivery Systems

    Science and Technology
    • 1st Edition
    • Vitthal S. Kulkarni
    • English
    With the improvements in formulation science and certain transdermal delivery technologies, the non-invasive mode of drug delivery is now ready to compete with traditional methods of oral and injectible routes of drug delivery. The Handbook of Non-Invasive Drug Delivery Systems encompasses the broad field of non-invasive drug delivery systems that include drug delivery via topical, transdermal-passive, transdermal-active (device- aided enhanced penetration), trans-mucosal membrane, trans-ocular membrane as well as delivery via alveolar membrane from inhaled medication. Patient compliance has been found to be much higher when administrated by non-invasive routes and therefore they are considered to be a preferred mode of drug delivery. The book includes both science and technological aspects of new drug delivery systems. Its unique focus is that it is on new drug delivery systems that are considered to be "non-invasive". Other unique features include a chapter on Regulatory Aspects of non-invasive systems and one on FDA guidance for topical nano-drug delivery. Two chapters covering market trends and perspectives, as well as providing guidance to those marketing such systems are also included.

  • Advances in Antiviral Drug Design

    • 1st Edition
    • Volume 3
    • E. De Clercq
    • English
    Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

  • Analytical Profiles of Drug Substances and Excipients

    • 1st Edition
    • Volume 26
    • English
    Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

  • Advances in Pharmacology

    • 1st Edition
    • Volume 46
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

  • Advances in Medicinal Chemistry

    • 1st Edition
    • Volume 4
    • B.E. Maryanoff + 1 more
    • English
    Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.

  • Medical Applications of Liposomes

    • 1st Edition
    • D.D. Lasic + 1 more
    • English
    The development of liposomes as a drug delivery system has fluctuated since its introduction in the late 1960's by A.D. Bangham. While academic research of liposomes as a model membrane system has always flourished, as the exponential growth of papers can testify, the application of these findings to medically useful products has gone through several crises. Following the original optimism in the 70's and early 80's, a period of severe skepticism ensued at the end of the 80's and beginning of the 90's, culminating in a moderate but real optimism in the mid 90's, as a result of a successful launch of the first products in the US and Europe.In this collection of papers, the editors have gathered the most promising ideas, approaches, applications and commercial developments, thereby presenting an up-to-date compilation of the present status of the field. This includes such broad areas as anti-cancer chemotherapy immune stimulation and infectious diseases. Currently, the major areas of progress are in delivery of anti-fungal agents by conventional liposomes or lipid-based carriers and systemic anticancer therapy using long-circulating liposomes. The future applications as characterized by the direction of present day research is in specific targeting and delivery of informational molecules such as DNA plasmids (genes), antisense oligonucleotides or ribozymes. Other future developments may be in topical delivery, vaccination and in diagnostics.Features of this book:• Contributions from almost all the leading labs in the field• Up-to-date, critical reviews bridged by editors' introductions• Organized into a logical framework.

  • Analytical Profiles of Drug Substances and Excipients

    • 1st Edition
    • Volume 25
    • English
    Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

  • The Many Faces of RNA

    • 1st Edition
    • D. S. Eggleston + 2 more
    • English
    The Many Faces of RNA is the subject for the eighth SmithKline Beecham Pharmaceuticals Research Symposia. It highlights a rapidly developing area of scientific investigation. The style and format are deliberately designed to promote in-depth presentations and discussions and to facilitate the forging of collaborations between academic and industrial partners.This symposium focuses on several of the many fundamental, advancing strategies for exploring RNA and its functions. It emphasizes the interplay between biology, chemistry, genomics, and molecular biology which is leading to exciting new insights and avenues of investigation. The book explores RNA as a therapeutic target, RNA as a tool, RNA and its interactions, along with chemical, computational, and structural investigations.

  • Side Effects of Drugs Annual

    • 1st Edition
    • Volume 19
    • English
    The very latest information on adverse drug effects from the international literature, compiled by an international team of experts.New reports are presented of adverse drug effects, critically analysed in context, in terms of clinical relevance and importance, and cross-referring to previous reports where necessary. New adverse effects are reported and evaluated, and previously reported adverse effects are re-evaluated in the light of the most recent information.Unique features:Reviews in which selected adverse effects are discussed in depth.Two separate indexes enhance the use of the book, allowing the reader to access information by drug name or by, adverse effects.

  • Advances in Pharmacology

    • 1st Edition
    • Volume 37
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

  • Advances in Antiviral Drug Design

    • 1st Edition
    • Volume 2
    • E. De Clercq
    • English
    The purpose of the series on Advances in Antiviral Drug Design is to regularly review the "state of the art" on emerging new developments in the antiviral drug research field, thereby spanning the conceptual design and chemical synthesis of new antiviral compounds, their structure-activity relationship, mechanism and target(s) of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use. Volume 2 begins with a description of the antiviral potential of antisense oligonucleotides by J. Temsamani and S. Agrawal. According to the aims of the anitsense technology, these oligonucleotides should be targeted at specific viral antisense technology, these oligonucleotides should be targeted at specific viral mRNA sequences so that translation to the virus-specified proteins is blocked; this has been achieved for a number of oligomers, some of which are now in clinical trials for the treatment of HIV, HCMV, and human papilloma virus (HPV) infections. Then C.-S. Yuan, S. Liu, S.F. Wnuk, M.J. Robins and R.T. Borchardt assess the role of S-adenosylhornocyste... (AdoHcy) hydrolase as target for the design of antiviral agents with broad-spectrum antiviral activity. This is followed by an in-depth account on the design and synthesis of a number of first-, second- and third-generation AdoHcy hydrolase inhibitors and their mode of action at the enzyme level.V.E. Marquez provides a comprehensive description of the various carbocyclic (carba) nucleosides that have been synthesized and evaluated for antiviral activity. Although the number and diversity of the carba-nucleosides that have been found to be antivirally active (or inactive) is astonishingly high, there is no limit to further expansion of this fascinating class of molecules. For the various nucleoside analogues that have to be intracellularly phosphorylated to the 5'-triphosphate stage, to interact with their target enzyme (i.e., herpesviral DNA polymerase or retroviral revers transcriptase) the first phosphorylation step is often the rate-limiting step, and thus various strategies are envisaged by C. Perigoud, J.-L. Girardet, G. Gosselin and J.-L. Bach on how to bypass this initial phosphorylation and to deliver the nucleoside 5'-monophophate directly inside the cells.The HIV protease has been considered as a paradigm for rational drug design. The enzyme is among the best understood in terms of both structure and action, and because of its crucial role in the maturation of HIV, it has been vigorously pursued as a target for anti-HIV chemotherapy. In their comprehensive review of the multidisciplinary approach towards the development of HIV protease inhibitors A.G. Tomasselli, S. Thaisrivongs and R.L. Heinrikson highlight those protease inhibitors which have been brought forward to clinical trials.

  • Advances in Pharmacology

    • 1st Edition
    • Volume 35
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

  • QSAR and Drug Design: New Developments and Applications

    • 1st Edition
    • Volume 23
    • H. Timmerman
    • T. Fujita
    • English
    Based on topics presented at the Annual Japanese (Quantitative) Structure-Activity Relationship Symposium and the Biennial China-Japan Drug Design and Development conference, the topics in this volume cover almost every procedure and subdiscipline in the SAR discipline.They are categorized in three sections. Section one includes topics illustrating newer methodologies relating to ligand-receptor, molecular graphics and receptor modelling as well as the three-dimensional (Q)SAR examples with the active analogue approach and the comparative molecular field analysis. In section 2 the hydrophobicity parameters, log P (1-octanol/water) for compound series of medicinal-chemical interest are analysed physico-organic chemically. Section 3 contains the examples based on the traditional Hansch QSAR approach.A variety of methodologies and procedures are presented in this single volume, along with their methodological philosophies.

  • Peptides

    Synthesis, Structures, and Applications
    • 1st Edition
    • Bernd Gutte
    • English
    In recent years, research has shown the importance of peptides in neuroscience, immunology, and cell biology. Active research programs worldwide are now engaged in developing peptide-based drugs and vaccines using modification of natural peptides and proteins, design of artificial peptides and peptide mimetics, and screening of peptide and phage libraries. In this comprehensive book, the authors discuss peptide synthesis and application within the context of their increasing importance to the pharmaceutical industry. Peptides: Synthesis, Structures, and Applications explores the broad growth of information in modern peptide synthetic methods and the structure-activity relationships of synthetic polypeptides.

  • Advances in Drug Research

    • 1st Edition
    • Volume 26
    • English
    Volume 26 continues the trend of shorter, more frequent volumes. With Volume 25, the series gained a new co-editor, Urs Meyer. While retaining the commitment to publish chapters on therapeutic or chemical classes and on general topics or concepts, the series' coverage has expanded to include methodological chapters, and new areas of recognized or potential significance to drug research, especially in molecular pharmacology.

  • Anesthesia and Cardiovascular Disease

    • 1st Edition
    • Volume 31
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Volume 31 deals with the mechanisms of anesthetic actions under normal conditions as well as pathophysiologic states.

  • Anesthesia and Cardiovascular Disease

    • 1st Edition
    • Volume 31
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Volume 31 deals with the mechanisms of anesthetic actions under normal conditions as well as pathophysiologic states.

  • Biochemistry of Redox Reactions

    • 1st Edition
    • Bernard Testa + 1 more
    • English
    Surpassing the 1976 book by Testa and Jenner, Drug Metabolism: Chemical and Biochemical Aspects (Dekker), this informative, up-to-date text includes the following features, unavailable elsewhere: First in a set of books to provide a comprehensive coverage of drug metabolism; Opening chapter provides a general introduction to the complete set of books; Other chapters cover reaction mechanisms, catalytic cycles, regio- and stereoselectivities, types of substrates, reactivity of intermediates, and drug-enzyme interactions; Extensive detailed diagrams of reaction pathways and chemical structures

  • Advances in Pharmacology

    • 1st Edition
    • Volume 28
    • English
    Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular basis of drug action, both applied and experimental.

  • Drug and Enzyme Targeting, Part A

    • 1st Edition
    • Volume 112
    • Nathan P. Colowick + 1 more
    • English
    The critically acclaimed laboratory standard, Methods in Enzymology, is one of the most highly respected publications in the field of biochemistry. Since 1955, each volume has been eagerly awaited, frequently consulted, and praised by researchers and reviewers alike. The series contains much material still relevant today - truly an essential publication for researchers in all fields of life sciences.

Related subjects